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Abstract
Disruption of circadian rhythm is believed to play a critical role in cancer development. Cryptochrome 1 (CRY1) is a core
component of the mammalian circadian clock and we have previously shown its deregulated expression in a subgroup of
patients with chronic lymphocytic leukemia (CLL). Using real-time RT-PCR in a cohort of 76 CLL patients and 35 normal
blood donors we now demonstrate that differential CRY1 mRNA expression in high-risk (HR) CD38+/immunoglobulin
variable heavy chain gene (IgVH) unmutated patients as compared to low-risk (LR) CD382/IgVH mutated patients can be
attributed to down-modulation of CRY1 in LR CLL cases. Analysis of the DNA methylation profile of the CRY1 promoter in a
subgroup of 57 patients revealed that CRY1 expression in LR CLL cells is silenced by aberrant promoter CpG island
hypermethylation. The methylation pattern of the CRY1 promoter proved to have high prognostic impact in CLL where
aberrant promoter methylation predicted a favourable outcome. CRY1 mRNA transcript levels did not change over time in
the majority of patients where sequential samples were available for analysis. We also compared the CRY1 expression in CLL
with other lymphoid malignancies and observed epigenetic silencing of CRY1 in a patient with B cell acute lymphoblastic
leukemia (B-ALL).
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Introduction
Accumulating epidemiological and genetic evidence indicates
that disruption of circadian rhythms may increase the susceptibil-
ity for developing cancer including non-Hodgkin lymphoma
(NHL) and also adversely affects tumor progression [1–5]. At the
molecular level, several genes constituting the clock machinery
have been found to establish functional interplays with regulators
of the cell cycle, and disrupted expression of these genes has been
shown to result in aberrant cell proliferation [2,3,6,7]. In a
previous study we first described disturbances in the molecular
circadian machinery of CLL cells and hypothesized that these
alterations may play a role in the molecular pathogenesis of the
disease [8]. In particular, we found that the core circadian gene
CRY1 is up-regulated in samples from high-risk ZAP-70+/CD38+
CLL patients as compared to their ZAP-702/CD382 counter-
parts which are characterized by a more benign clinical course
[8,9]. Therefore, based on these data we and others have proposed
that CRY1 may serve as a novel prognostic factor which could be
useful for the clinical management of CLL patients [8–11].
Functionally, CRY1 has been shown to be essential to the
maintenance of circadian rhythm because of its role in the
negative arm of the circadian feedback loop [12]. However,
independent of its circadian function it may have an additional
role as a transcriptional regulator of a number of genes involved in
cell metabolism and proliferation [4,6,12,13]. In the current study
we further investigated the role of CRY1 by comparing its
expression pattern in molecularly defined CLL subgroups to that
of B cells obtained from the peripheral blood of normal donors.
Furthermore, we aimed to determine the molecular mechanism(s)
underlying deregulated CRY1 expression in CLL.
Materials and Methods
Patients and samples
Peripheral blood samples from 76 CLL patients and 35 normal
donors (ND) were analyzed after obtaining written consent
according to our institutional guidelines, approved by the Ethics
Commission of the University of Essen-Duisburg. The diagnosis of
CLL required a persistent lymphocytosis of more than 5.0610
9/l
and a typical CD19
+, CD20
+, CD5
+, CD23
+, Ig light chain (k or l
light chain) restricted immunophenotype as revealed by flow
cytometry of peripheral blood cells [14]. Blood samples from CLL
patients and ND were drawn in the morning hours and
immediately processed. Peripheral blood mononuclear cells
(PBMC) were isolated by Lymphoprep density gradient centrifu-
gation (Invitrogen, Karlsruhe; Germany) and cryopreserved until
further analysis. Patient selection for this study was based on the
availability of viably frozen DMSO preserved PBMC and/or
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and laboratory data of the study population are shown in Table 1.
Five healthy donors and a subgroup of 57 CLL patients were
subjected to DNA methylation analysis. Patient characteristics of
this subgroup are shown separately in Table S1. For this set of
experiments CD19+ cells were positively selected from PBMCs
employing the EasySep Human CD19 Selection Kit (StemCell
Technologies, Canada) according to the manufacturer’s instruc-
tion resulting in a .90% purity of CD19+ B cells. DNA was
isolated from the immunomagnetically purified CD19+ cell
fraction using the DNeasy Blood and Tissue Kit (Qiagen, Hilden,
Germany).
Flow cytometry
Cell surface expression of CD38 was examined by flow
cytometry using a previously described panel of fluorochrome-
labeled monoclonal antibodies (CD38 PE, clone HB7) in a
standard three-color flow cytometry approach using a 20% cut-off
to define CD38 positivity [15,16].
Fluorescence in situ hybridization (FISH)
Prognostically relevant anomalies of chromosomal regions 11q,
13q, and 17p, and of chromosome 12 were assessed by
fluorescence in situ hybridization, as described previously [16].
Real-time reverse-transcriptase-PCR (qRT-PCR)
Total RNA from PBMC was extracted with RNeasy Midi Kit
(Qiagen, Hilden, Germany) and spectrophotometrically quantified
as previously described [8]. First strand DNA was synthesized
from 1 mg of RNA using oligo(dT) primers employing a
commercially available kit (RT-PCR Amplimers, Becton Dick-
inson, Heidelberg, Germany) according to the manufacturer’s
instructions. Real-Time PCR was performed with the ABI Prism
7900HT Sequence Detector (Applied Biosystems, Foster City, CA,
USA) using the TaqMan Universal PCR Master Mix protocol
(Applied Biosystems). Specific assays for CRY1 (Hs00172734_m1,
Assays-on-Demand Gene Expression System, Applied Biosystems),
BMAL1 (Hs00154147_m1, Assays-on-Demand Gene Expression
System, Applied Biosystems), CLOCK (Hs00231857_m1, Assays-
on-Demand Gene Expression System, Applied Biosystems), PER1
(Hs00242988_m1, Assays-on-Demand Gene Expression System,
Applied Biosystems), PER2 (Hs00256144_m1, Assays-on-Demand
Gene Expression System, Applied Biosystems) and GAPDH
(Hs99999905_m1, Assays-on-Demand Gene Expression System,
Applied Biosystems) were used. All reactions were carried out in a
10 ml final volume containing 5 ml Master Mix, 0.5 ml of the
specific assay and 4.5 ml of 1:2 diluted cDNA. The amplification
was performed under following conditions: 95uC for 10 min
followed by 40 cycles of denaturation at 95uC for 15 s and
annealing/elongation at 60uC for 1 min. Standard curves for all
assays show similar gradients (coefficient of variation 6.8%, data
not shown). CRY1 mRNA expression was normalized against the
housekeeping gene glyceralaldehyde-3-phosphate dehydrogenase
(GAPDH) as endogenous reference by computing the difference
between the respective Ct values (DCt=Ct[gene]2Ct[GAPDH]).
All PCR reactions were performed in duplicate (mean coefficient
of variation for all target genes was below 1%). The mean
threshold cycle number (Ct) for each tested mRNA was used to
quantify the relative expression of each gene: 2
2DCt.
DNA methylation analysis of the CRY1 gene by bisulphite
genomic sequencing. Bisulphite treatment of genomic DNA
was carried out using the EpiTect Bisulphite Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instruction. The
primers for amplifying bisulphite-modified DNA were: CRY1-
forward: 59-TTTGTGAGGGAAGGTTTAGTTT-39, CRY1-
reverse: 59-AACAATTTCCAAACCCTCC-39. For possible
sequencing of the PCR product we attached a tag (forward 59-
CTTGCTTCCTGGCACGAG-39, reverse 59-CAGGAAACAG-
CTATGAC-39). The PCR was carried out as follows:
denaturation at 95uC for 10 minutes followed by 35 cycles
comprising a second denaturation of 30 seconds at 94uC,
annealing at 61uC for 30 seconds and extension at 72uC for
45 seconds, followed by 7 minutes elongation at 72uC. The
sequence of the PCR product is depicted in Figure S1. PCR
products were separated by agarose gel electrophoresis, excised
and purified by gel extraction with MinElute Gel Extraction Kit
(Qiagen, Hilden, Germany). PCR products were ligated into
pGEMH-T Easy Vector (Promega, Madison, USA) and
transformed in XL1-Blue Competent Cells (Stratagene, La Jolla,
CA, USA). Plasmid DNA isolated from multiple colonies derived
from each PCR product were sequenced using the CRY1 reverse
primer on an ABI 3130 Genetic Analyzer.
DNA methylation analysis of the CRY1 gene by Bisulphite
MassArray assays. Bisulphite treatment of genomic DNA was
carried out using the EpiTect Bisulphite Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instruction. The
reverse primer contained a T7-promoter tag for in vitro
transcription (59-cagtaatacgactcactatagggagaaggct-39) and the
forward primer was tagged with a 10 mer (59-aggaagagag-39).
Bisulphite-treated DNA was PCR amplified (denaturation at 95uC
for 10 minutes followed by 40 cycles comprising a second
denaturation of 30 seconds at 95uC, annealing at 61uC for
Table 1. Patient characteristics.
Parameter No. of patients (%)
Total No. 76
Sex male 53 (70)
female 23 (30)
Age, years median 61
range 32–86
Follow-up, months median 78.0
Binet Stage at diagnosis A 53 (70)
B 17 (22)
C 4 (5)
n.a. * 2 (3)
Binet Stage at last follow-up A 24 (32)
B 14 (18)
C 12 (16)
n.a. * 26 (34)
CD38 expression ,20% 40 (52)
$20% 36 (48)
IgVH mutational status unmutated 21 (28)
mutated 21 (28)
n.a. * 34 (44)
FISH cytogenetics favorable 33 (43)
unfavorable 22 (29)
Treatment history untreated 42 (55)
treated 32 (42)
*n.a., not available.
doi:10.1371/journal.pone.0034347.t001
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10 minutes elongation at 74uC), PCR products were purified by
gel extraction with MinElute Gel Extraction Kit (Qiagen, Hilden,
Germany). 5 mL of the PCR product were used for the assay.
Bisulphite MassArray assays were performed by the Genomics
Core Facility, Albert Einstein College of Medicine. The data were
analyzed using the analytical pipeline previously published [17].
DNA quality and no-template controls, 0%, and 100% methylated
DNA were included in all assays.
50 K SNP array analysis of CRY1 copy number at
chromosome 12q23. For SNP array studies, genomic DNA
was extracted from CD19 positively selected PBMCs using the
QIAamp blood kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions. Array experiments were performed
according to the standard protocol for Affymetrix GeneChip
Mapping 50 K arrays (Affymetrix). Briefly, a 250 ng sample of
DNA was digested with XbaI, ligated to adaptors, amplified by
PCR, fragmented with DNAse I, and biotin-labeled. The labeled
samples were hybridized to the Affymetrix 50 K SNP XbaI
mapping array (Affymetrix Inc., Santa Clara, CA) followed by
washing, staining and scanning.
The acquired signal data was normalized with the dChip [18]
program, using model-based expression, perfect match (PM)-only
background subtraction and quantiles as probe-selection method.
The normalized signal was then used as raw copy number per
SNP and further analyzed by the GLAD algorithm [19] included
in the GenePattern [20] suite, which segmented the data and
assigned aggregated copy numbers to segments. A segment was
defined as aberrant if its copy number was below 1.7 (loss) or
above 2.3 (gain). The resulting list of aberrant regions was in
addition filtered for regions consisting of more than 10 SNPs to
exclude regions resulting from random noise in the copy number
signal.
Statistical analysis
Comparisons of clinical and biological parameters between
subgroups were carried out using the Mann-Whitney-U test for
continuous variables and Fisher’s exact test for categorical data.
Correlation between CRY1 delta CT and percentage of promoter
methylation was tested using Spearman correlation. The Wilcoxon
test for paired samples was used to compare CRY1 delta CT
analysed in B and T cells from ND. Survival analysis was carried
out with the Kaplan-Meier method and differences in treatment
free survival between risk groups were tested with the log-rank test.
All analyses were performed using R statistical software version
2.10.1 (R Development Core Team, Vienna, Austria, http://
www.r-project.org) and GraphPad Prism Version 5.04 (GraphPad
Software).
Results
Analysis of CRY1 expression in normal donor derived vs.
CLL PBMC
We measured the mRNA expression of the circadian gene
CRY1 in peripheral blood mononuclear cells (PBMC) containing
more than 80% CD19+CD5+ leukemic B cells as determined by
multiparameter flow cytometry in a cohort of 76 CLL patients
(Table 1). In line with our previously published work [8,9] we
observed significantly higher CRY1 mRNA levels in high-risk(HR)
patients defined by the expression of CD38 and/or unmutated
IgVH genes as compared to their CD38 negative and/or IgVH
mutated low risk (LR) counterparts (Figure 1A, 1B). We could also
confirm the prognostic value of CRY1 expression in CLL by
comparing the clinical outcome of CLL patients with high vs. low
CRY1 expression using the median DCt value as a cut-off.
Significant differences in treatment free survival (TFS) were
observed between the two groups (Figure S2). Of note,
comparative analysis with PBMC derived from age matched
normal blood donors revealed that these expression differences
can be attributed to an under-expression of CRY1 in LR CLL
cases rather than over-expression in the HR group (Figure 1A,
1B). As the cellular composition of normal PBMC and PBMC
isolated from CLL patients is known to vastly differ with regard to
the content of B and T cells we compared mRNA expression levels
of CRY1 in immunomagnetically purified CD19+ B cells and
CD3+ T cells from normal donors (Figure S3). CRY1 expression
Figure 1. Expression of CRY1 in CLL subgroups and normal
donors. CRY1 mRNA expression in normal donors (ND, n=35) in
comparison to CLL samples from prognostic subgroups defined by
CD38 expression (A, CD38+ samples, n=36 vs. CD382 samples, n=39)
and IgVH mutational status (B, IgVH unmutated/V3-21, UM/V3-21,
n=23 vs. IgVH mutated, M, n=18). mRNA levels are relative to GAPDH.
Data are presented in a box-and-whisker format: the difference of the
25th and 75th percentile form the box (interquartile range, IQR), with
the median marked as a line; the whiskers go down to the smallest
value and up to the largest values. The Mann-Whitney U-test was used
to compute p-values for pairwise comparisons.
doi:10.1371/journal.pone.0034347.g001
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that under-expression in LR CLL samples relative to ND controls
reflected true down-regulation of the gene in the leukemic cells
rather than differences in the cellular composition of the PBMC
samples.
Dysregulation of CRY1 in CLL cannot be explained by
chromosomal aberrations
Aiming at investigating the molecular mechanism(s) underlying
disrupted CRY1 expression in CLL cells we then speculated that
this phenomenon may be explained by aberration of this gene at
chromosome 12q23–q24.1. Exploiting a panel of CLL cases which
had been previously investigated for the presence of structural
chromosomal abnormalities [21] by high resolution SNP array
profiling we could not detect loss of chromosomal material at the
CRY1 locus in any of the 55 individual CLL samples analyzed
(data not shown). Moreover, an elevated copy number at this
position is only detected for samples harbouring a trisomy 12, all
other samples exhibit the regular two copies of this gene. The CLL
patient cohort of this study (n=76) comprises 12 cases with a
trisomy 12. Among the CD38+ population 10 patients had a
trisomy 12 whereas 14 were negative. Among the CD382 patients
2 had a trisomy 12 whereas 28 subjects proved to be negative. No
differences in CRY1 mRNA expression were noted neither in the
CD38+ nor the CD382 subgroups defined by the presence or
absence of trisomy 12 (p=0.54 and 0.49, respectively).
DNA methylation analysis of the CRY1 gene
As CRY1 has been previously shown to undergo aberrant DNA
methylation events in various human cancers [7,22], we then
examined whether epigenetic silencing could explain CRY1
mRNA expression differences in CLL. DNA methylation was
studied within the promoter region of the CRY1 gene (Figure S1)
employing sequencing of cloned PCR products generated from
bisulphite-modified DNA extracted from immunomagnetically
purified CD19+ B cells from the peripheral blood of CLL (N=14)
and normal donors (N=4). We observed that patients with low
CRY1 expression show hypermethylation of the analyzed region
in comparison to patients with a high CRY1 expression and
normal donors (Figure 2A). Using the Sequenom MassArray
Compact System for methylation analysis in the same CRY1
promoter region we then confirmed these results in a cohort of 58
CLL samples and 5 normal donors (Figures 3A and S4, Table S3).
LR CLL patients either defined by CD38 or IgVH mutational
status showed a significantly higher degree of methylation of the
CRY1 promoter in comparison to the HR group. In all, there was
a statistically highly significant inverse correlation between the
percentage of methylated CpGs and CRY1 mRNA expression as
detected by qRT-PCR (Figure 2B and 3B). Comparing both
methods for methylation analysis a high correlation (r=0.89,
Figure 2. Analysis of CRY1 CpG island promoter methylation
status measured by bisulphite genomic sequencing. A Results of
bisulphite genomic sequencing performed on 6–12 clones of 4 normal
donors (ND) and 12 different CLL samples. Top, schematic depiction of
the analyzed area of the CRY1 CpG island around the transcription start
site (horizontal black line). Short vertical lines represent CpG
dinucleotides. The location of PCR primers are indicated as bold black
horizontal arrows. Presence of methylated or unmethylated CpG
dinucleotides is indicated by solid or open squares respectively, blue
squares indicate not analyzable CpG dinucleotides. The mean standard
error for all samples is 1.99 reflecting the low variability between the
methylation profile of each analyzed clone. At the right hand side of
each graph, first the percentage of methylated CpGs for each individual
sample is depicted, below is the percentage of methylated CpGs
measured by Bisulphite MassArray and at the bottom each sample’s
CRY1 mRNA expression relative to GAPDH is shown. B Samples from
CLL patients and ND were subjected to both CRY1 mRNA expression
and DNA methylation analysis by bisulphite genomic sequencing.
mRNA expression values and percentage of methylated CpG were
found to be highly correlated (r=20.62, p=0.006, Spearman correla-
tion). The regression line in the plot was produced by linear regression
analysis using promoter methylation as dependent and CRY1 mRNA
expression as independent variable (open circles indicate ND).
doi:10.1371/journal.pone.0034347.g002
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applied methods (Figure 3C).
Prognostic value of CRY1 methylation pattern in CLL
To assess the prognostic value of the methylation profile of the
CRY1 promoter we defined two groups, i.e. patients with lowly
methylated and highly methylated promoter region. The threshold
value of 9% was derived from the median value of the CLL
samples subjected to MassArray methylation analysis. On survival
analysis patients with a highly methylated CRY1 promoter region
exhibited a significantly longer treatment-free survival as com-
pared to the hypomethylated patient subgroup (Figure 4).
Analysis of CRY1 expression over time
Twenty-seven patients were studied at two or more time points
using the qRT-PCR assay. As illustrated in Figure S5, CRY1
mRNA expression was relatively stable over time in the majority of
patients with stable disease (10/13 (77%), Figure S5, left panel) as
well as in patients with progressive disease (12/14 (86%), right
panel). The fact that three of the five patients with increasing
CRY1 mRNA levels had a comparably benign course of disease
may suggest that changes in CRY1 expression over time are not
stringently related to disease progression. Moreover, in 6 of the 14
patients (marked by arrows in Figure S5) with a progressive course
of the disease first treatment was initiated after collection of the
baseline sample in this longitudinal analysis. Although all these
patients responded to therapy, no reduction in CRY1 mRNA
expression could be documented. It is noteworthy that we did not
observe a single case with decreasing CRY1 mRNA levels during
follow-up in the entire cohort of patients with samples available for
sequential analysis.
Interestingly, one patient with a low baseline CRY1 expression
and a correspondingly high degree of CpG island methylation
experienced disease progression as evidenced by rising lymphocyte
counts and transition from Binet stage A to stage C disease.
Increasing CRY1 expression in this particular patient was shown
to be associated with loss of CRY1 promoter hypermethylation
(Figure S6).
Analysis of the role of CRY1 within the circadian clock’s
transcription/translation-based feedback loop in CLL
At the molecular level, circadian rhythms are encoded by an
autoregulatory loop composed of a set of transcription activators
(CLOCK/BMAL1) that induce expression of PER and CRY.
Accumulated PER and CRY proteins in turn inhibit BMAL1/
CLOCK transcriptional activity and repress their expression.
Thus, aberrant silencing of CRY1 expression in LR CLL may be
associated with dysregulated expression of other circadian genes.
Indeed, we could observe increased PER2 and CLOCK mRNA
levels in CLL as compared to ND derived PBMC, whereas mRNA
levels of BMAL1 and PER1 were similar in both groups (Figure
Figure 3. Analysis of CRY1 CpG island promoter methylation
status measured with the Bisulphite MassArray assay. A Results
of CRY1 CpG island methylation analysis performed on CLL samples and
normal donors (ND) grouped by CD38 expression (CD382 samples,
n=28; CD38+ samples, n=30; ND, n=5). Each value represents the
average amount of methylated CpGs of all analyzable CpGs within the
CpG island promoter from one patient. The values represent the mean
of duplicate experiments. The IgVH mutational status of each patient (if
available) is highlighted in red; circles and squares indicate unmutated
IgVH/V3-21 and mutated IgVH status, respectively. The median is
marked as a line, error bars indicate SEM. Unpaired two-tailed t-test was
used to compute p-values. B Samples from CLL patients and ND were
subjected to both CRY1 mRNA expression and DNA methylation
analysis with the bisulphite MassArray assay. mRNA expression values
and percentage of methylated CpG were found to be highly correlated
(r=20.63, p,0.0001, Spearman correlation). The regression line in the
plot was produced by linear regression analysis using promoter
methylation as dependent and CRY1 mRNA expression as independent
variable. C Correlation between the methylation data resulting from
bisulphite genomic sequencing and the MassArray method showed
high consistency (r=0.86, p,0.0001, Spearman correlation).
doi:10.1371/journal.pone.0034347.g003
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noted in both LR and HR CLL samples and could not be related
to alterations in CRY1 expression (Figure S7) suggesting that these
abnormalities may occur independently of each other.
Analysis of CRY1 expression and CpG island
hypermethylation in other hematologic malignancies
From a cancer biology standpoint we next wanted to test
whether deregulated CRY1 expression may also be observed in
other lymphoid malignancies than CLL. To this end we employed
the CRY1 qRT-PCR assay to screen RNA samples isolated from a
wide range of lymphoproliferative disorders including T prolym-
phocytic leukemia (T-PLL, n=10), mantle cell lymphoma (MCL,
n=6), hairy cell leukemia (HCL, n=3), multiple myeloma (MM,
n=8), plasma cell leukemia (PCL, n=2) and B and T lineage
acute lymphoid leukemia (n=29 resp. n=19). In disease entities
with more than 5 observations, statistical comparisons with ND
derived PBMC did not reveal significant expression differences
(Figure 5A). However, this finding needs to be interpreted with
caution because of the small numbers of samples tested in this
series. The availability of a comparably large number of ALL
samples (n=48) allowed for a more detailed analysis of this disease
group. The clinical characteristics of this patient cohort are given
in Table S2. Similar to its distribution in CLL, CRY1 expression
in ALL was found to be very heterogeneous where one patient
with a mature B-ALL exhibited a markedly low CRY1 transcript
level (Figure 5A). This particular sample demonstrated a high
degree of CRY1 promoter methylation while two other ALL
samples with a higher CRY1 expression were nearly completely
demethylated (Figure 5B).
Next we investigated the prognostic value of CRY1 expression
in ALL. To this end we compared the clinical outcome of ALL
patients with high vs. low CRY1 expression using the median DCt
value as a cut-off. No significant differences in overall survival (OS)
were observed between the two groups (Figure S8).
Discussion
In this study, we analyzed the expression of CRY1 mRNA,
which encodes a key component of the central and peripheral
circadian oscillator, in the PBMC from normal blood donors and
patients with CLL [8,11,23,24]. In line with our previous work
[8,9] and that of others [10,11] we detected elevated CRY1
transcript levels in patients with high risk disease defined by the
expression of CD38 and/or unmutated IgVH (UM) genes as
compared to their CD38 negative and/or IgVH mutated (M) low
risk (LR) counterparts. Lewintre et al. confirmed these results in a
recently published microarray-based gene expression profiling
study including 36 patients with early-stage CLL [11]. Therefore,
determination of CRY1 may have potential as a novel prognostic
marker in CLL and should be tested in comparison to other
established molecular risk factors in the setting of prospective
randomized trials.
We now uncover that HR CLL cases and ND derived B cells
exhibit comparable levels of CRY1 mRNA expression. Thus,
disrupted CRY1 expression in CLL can be attributed to down-
modulation of CRY1 in LR CLL cases rather than over-
Figure 4. Treatment-free survival according to the methylation status of the CRY1 promoter region. Treatment-free survival of 53 CLL
patients with lowly methylated (n=26) and highly methylated (n=27) CRY1 promoter.
doi:10.1371/journal.pone.0034347.g004
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molecular mechanisms underlying down-regulation of CRY1 in
LR CLL. As CRY1 had been previously shown to undergo
aberrant DNA methylation events in various solid human
malignancies including breast and ovarian cancers [3,7,22], we
examined whether epigenetic silencing could also explain the
observed CRY1 mRNA expression differences in CLL subgroups.
To this end we performed comparative DNA methylation analysis
of highly purified CD19+ B cells from the peripheral blood of 57
CLL patients and normal donors. Indeed, our results show that
CRY1 is transcriptionally silenced by promoter hypermethylation
in LR CLL cases while HR cases and ND derived B cells exhibit
hypomethylated CRY1 promoter regions. Importantly, DNA
methylation analysis was complemented by qRT-PCR performed
on the same samples revealing a statistically highly significant
inverse correlation between the percentage of methylated CpGs
and CRY1 mRNA expression in individual cases, suggesting a
direct regulation of CRY1 expression through methylation of its
promoter. We could show that the methylation status of the CRY1
promoter predicts clinical outcome in CLL patients; where
aberrant hypermethylation was associated with a more benign
course of the disease. To date, only few reports describe an
aberrant methylation phenotype as a predictor of outcome in
haematological diseases. Recently, Irving et al reported a panel of
methylation markers (CD38, HOXA4, BTG4) in which an overall
methylation score was significantly associated with time to first
treatment in CLL [25]. Olk-Batz et al [26] described that a high
methylation profile is associated with an aggressive biological
variant of juvenile myelomonocytic leukemia.
As stability of CRY1 expression by the leukemic cell clone over
time is an important prerequisite for its reliable use as a prognostic
marker [27], we sequentially analyzed CRY1 expression in 27
patients. CRY1 transcript levels were remarkably stable in the
majority of patients and no consistent changes were noted in
relation to alterations in disease activity and treatment history of
individual patients. Significant expression changes during follow-
up occurred in 19% of the patients, which could limit the value of
this marker under routine clinical conditions. However, these
findings are limited by the comparably small number of CLL cases
analyzed in this study and thus need to be validated in a larger
patient cohort. In one patient with a low baseline CRY1
expression and a correspondingly high degree of CpG island
Figure 5. Comparative analysis of CRY1 expression in a panel of different lymphoid malignancies. qRT-PCR analyses of PBMC samples
obtained from patients with T-prolymphocytic leukemia (T-PLL), mantle cell lymphoma (MCL), plasma cell leukemia (PCL), hairy cell leukemia (HCL), B
and T cell acute lymphoblastic leukemia (B-ALL, T-ALL), CLL and normal donors (ND), A. Red characters indicate samples that were further subjected
to DNA methylation analysis of the CRY1 promoter, A. Analysis of CRY1 CpG island promoter methylation status, B. For experimental details and
description of the graph in panel B refer to the legend of Figure 2.
doi:10.1371/journal.pone.0034347.g005
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expression and hypomethylation of the CRY1 promoter region. In
aggregate, these findings raise the possibility that epigenetic
silencing of CRY1 occurs early in the disease and may be lost
during disease progression at least in rare cases. Conversely, it
appears unlikely that the leukemic cells acquire epigenetic
silencing of CRY1 during the course of the disease as none of
the 27 patients in the longitudinal analysis showed a decrease of
CRY1 expression. It would be interesting to further investigate this
hypothesis by systematically comparing the prevalence of CRY1
methylation events in individuals with monoclonal B cell
lymphocytosis with Binet stage A, B and C CLL patients.
While differential CRY1 expression in HR vs. LR CLL
subgroups is now well established [8–11,28], the functional
consequences of CRY1 down-modulation in the leukemic cells
are currently unknown. It is tempting to speculate that epigenetic
silencing of CRY1 may contribute to the benign clinical behaviour
of LR CLL cases. At first sight this notion appears counterintuitive
to the general conception that the core components of the
molecular clock machinery may function as tumor suppressor
genes [29–32]. This view is mainly based on epidemiological and
genetic evidence indicating that disruption of circadian rhythms
might be directly linked to cancer development including non-
Hodgkin-lymphoma [2,5,33–35]. While the circadian genes PER1
and PER2 have been clearly shown to function as tumor
suppressors in the mouse model [30], a recent study showed that
epidermal deletion of BMAL1 in a transgenic mouse model which
spontaneously develops squamous tumours leads to significantly
fewer neoplastic lesions [36]. Along the same line transgenic CRY
deficient mice do not show a predisposition to cancer [6].
Furthermore and somewhat unexpectedly, ablation in the mouse
of both CRY genes in a TP53
2/2 background delays the onset of
cancer [13]. This latter observation supports our hypothesis that
epigenetic silencing of CRY1 may functionally contribute to the
indolent clinical behaviour of LR CLL. It is currently unclear
whether abrogation of one CRY gene, i.e. CRY1 or CRY2 suffices
to fully block the circadian rhythmicity of an individual cell.
Studies comparing the biologic characteristics of transgenic mice
lacking either one or both CRY genes indicate a certain degree of
functional redundancy [37].
Another matter of controversy is whether circadian rhythmicity
per se or only certain core clock components are involved in
tumorigenesis [4]. To address this issue we correlated CRY1
mRNA expression with other components of the circadian clock’s
transcription/translation-based feedback loop in individual CLL
samples. Recently, a number of in vitro and animal studies have
further elucidated the important functional role of CRY proteins
for the regulation of the molecular clock. For example, work by Ye
et al [38] demonstrated that CRY directly interacts with the
BMAL1:CLOCK:E-box complex independent of PER resulting in
inhibition of the transactivator function of CLOCK:BMAL1.
Furthermore, Busino et al. [39] showed in an in vitro model that
Cry1
2/2 Cry2
2/2 mouse embryonic fibroblasts are characterized
by a loss of oscillation in Per1 and Per2 and exhibit increased Per2
but not Per1 mRNA transcript levels in comparison to control
fibroblasts isolated from CRY wild type animals.
Here, we found that the expression of PER2 and CLOCK but
not BMAL1 and PER1 are also disrupted in CLL as compared to
ND derived control samples. However, contrary to what could be
expected from above described findings [38,39] these abnormal-
ities could neither be correlated with changes in CRY1 expression
nor the clinical course of the disease in individual CLL cases. In
aggregate, these latter results clearly suggest that defects in the
circadian molecular machinery may be a common phenomenon in
CLL cells and are not restricted to CRY1. Ongoing work in our
laboratory is aimed at determining the molecular and cellular
consequences of silencing different circadian genes in CLL cells in
vitro using siRNA oligonucleotide technology.
Finally, we wanted to determine whether CRY1 expression may
also be disturbed in other lymphoid malignancies than CLL. To
this end we measured CRY1 transcript levels in PBMC samples
from a range of different disease entities including T-PLL, MCL,
HCL, MM, PCL and B and T cell ALL. In a subgroup analysis
focussing on ALL we found a heterogeneous expression pattern
comparable to that observed in CLL. One patient with a mature
B-ALL exhibited a particularly low CRY1 expression which
correlated with a high degree of promoter methylation, suggesting
that aberrant epigenetic silencing of this gene may also occur in
other lymphoid disease entities. However, contrary to CLL
survival analysis did not show a significant difference between
ALL patients with high and low expression of CRY1, respectively.
In conclusion, our data indicate that the previously reported
CRY1 gene expression differences in LR vs. HR CLL patients
[8,11] are caused by aberrant methylation of the CRY1 promoter
in the LR patient subgroup. To our knowledge this is the first
report in CLL research linking epigenetic silencing of a specific
gene to an indolent clinical course of the disease.
Supporting Information
Figure S1 Map of CRY1 located on chromosome
12q23.3. The chromosomal location and nucleotide sequence
of CRY1 on chromosome 12q23.3 (indicated by the red vertical
line) extending from 105,909,272–106,011,728. CRY1 has one
CpG island consisting of 130 CpGs depicted as the green box
(106,010,743–106,011,941). Methylation analyses were performed
within this CpG island from 106,011,737–106,011,970. Red
letters indicate the primer sequences used for DNA methylation
studies.
(TIF)
Figure S2 Kaplan-Meier curves for treatment-free sur-
vival in CLL according to high and low expression of
CRY1. The median CRY1 DCT value was used as a cut-off to
define patient subgroups with high and low CRY1 mRNA
transcript levels. Figure S2 illustrates the treatment-free survival in
73 CLL patients with high/low CRY1 mRNA levels. Statistical
differences were analyzed by log-rank test.
(TIF)
Figure S3 Comparative analysis of CRY1 expression in
normal B and T cells. qRT-PCR analysis of immunomagne-
tically purified CD19+ B vs. CD3+ T cells obtained from five
normal donors. Statistical comparisons were performed using the
Wilcoxon test for paired samples.
(TIF)
Figure S4 Detailed results of CRY1 CpG island promot-
er methylation measured with Bisulphite MassArray
assays. Results of CRY1 CpG island methylation analysis
performed on further 58 CLL samples subdivided by CD38
expression (CD382 samples, n=28, CD38+ samples, n=30, ND,
n=5). Each row represents the methylation profile of one
individual patient. Putative fragmentation patterns are shown for
T -cleavage reaction on the plus strand of an amplicon of the
human genome. CG dinucleotides (filled circles) are numbered
and color-coded according to their ability to be assayed, where
gray indicates that the CG is located on a fragment whose
molecular weight is outside the usable mass window, red indicates
a molecular weight overlap with another fragment and blue
Epigenetic Silencing of CRY1 in CLL
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shown in corresponding colors, yellow highlights primer sequenc-
es. Methylation data are shown as an average from duplicates. Bar
height denotes percent methylation on a scale from 0% (low) to
100% (high), error bars indicate median absolute deviation. CG
sites that are putatively outside the usable mass window are
indicated as boxes with gray background.
(TIF)
Figure S5 Analysis of CRY1 expression over time. In all,
27 patients were analyzed for CRY1 expression using qRT-PCR
at two or more time points. Each line represents an individual
patient. The left graph depicts 13 patients with a stable course of
disease, on the right 14 patients with progressive disease are
shown. Three patients indicated with dashed lines had a
progressive disease but were not treated (right graph). Those
patients receiving first line chemotherapy after collection of the
first sample (baseline) are highlighted by individual colors whereas
the time point of first therapy is indicated by vertical arrows.
mRNA expression values are normalized to each patient’s
baseline, which is set to 1.
(TIF)
Figure S6 Time course analysis of CRY1 mRNA expres-
sion and CpG island promoter methylation in patient
#13 showing disease progression during follow-up.
Methylation analyses in panel B correspond to samples obtained
at baseline (a) and after 24 months of follow-up (b). For
experimental details and description of the graph in panel B refer
to the legend of Figure 2.
(TIF)
Figure S7 Analysis of circadian gene transcript levels in
CLL cells by qRT-PCR. Figure S7 shows PER1, PER2,
CLOCK and BMAL1 expression in normal donors (ND, n=24)
in comparison to CLL samples from prognostic subgroups defined
by CD38 expression (CD38+samples, n=24 vs. CD382 samples,
n=27). mRNA expression is relative to GAPDH. Data are
presented in a box-and-whisker format: the difference of the 25th
and 75th percentile form the box (interquartile range, IQR), with
the median marked as a line; the whiskers go down to the smallest
value and up to the largest values. The Mann-Whitney U-test was
used to compute p-values for pairwise comparisons.
(TIF)
Figure S8 Kaplan-Meier curves for overall survival in
ALL according to high and low expression of CRY1. The
median CRY1 DCT value was used as a cut-off to define patient
subgroups with high and low CRY1 mRNA transcript levels.
Figure S8 illustrates the overall survival for 48 patients with ALL
according to high and low expression of CRY1 mRNA levels.
Statistical differences were analyzed by log-rank test.
(TIF)
Table S1 Characteristics of CLL patients tested for
CRY1 promoter hypermethylation.
(DOCX)
Table S2 Clinical characteristics of ALL patients.
(DOCX)
Table S3 Individual methylation profile (MassArray
assay) and CRY1 expression values.
(DOCX)
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